A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates

Sponsor
Novo Nordisk A/S
Study ID
NCT03823339
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Insulin degludec/liraglutide — DRUG
    Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.

Study Details

The purpose of the study is to collect information on how Xultophy® works in patients with type 2 diabetes. The participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 26-34 weeks. The participants will be asked questions about their health and their diabetes treatment as part of their normal study doctor's appointment.

Key Dates

Start date
Jan 29, 2019
Status verified
Sep 2021
Primary completion
Dec 14, 2020
Completion
Dec 14, 2020

Study Design

Enrollment
300 participants (actual)

Arms

  • Arm: Patients with type 2 diabetes (T2DM)
    Patients with T2DM treated with any basal insulin or glucagon-Like peptide-1 receptor agonist (GLP-1 RA) (including once weekly GLP-1 RA) with/without oral antidiabetic drug (OAD) treatment, and with inadequate glycaemic control, for whom the physician had decided to intensify their treatment with Xultophy®

Primary Outcome Measure

Change in laboratory measured glycosylated haemoglobin A1c (HbA1c) [ Time Frame: From baseline [≤12 weeks prior to treatment initiation [week 0]) to end of study (26-34 weeks) ]

Related Studies